Given that SYCP2 has been reported as aberrantly expressed in ovarian and breast cancers—where its overexpression is associated with resistance to therapies targeting the DNA damage response [73]—it is plausible that SYCP2L may exhibit similar aberrant activation in the context of ASCC. This evidence concerns the gene SYCP2L and breast carcinoma.